Search Results

FRAX597 10 mg  | 99.75%

TargetMol

FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).

More Information Supplier Page

FRAX597 25 mg  | 99.75%

TargetMol

FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).

More Information Supplier Page

FRAX597 5 mg  | 99.75%

TargetMol

FRAX597 is an effective, ATP-competitive inhibitor of group I PAKs, and for PAK1(IC50=8 nM), PAK2(IC50=13 nM), and PAK3 (IC50=19 nM).

More Information Supplier Page

LY404039 10 mg  | Purity Not Available

TargetMol

LY404039 is an effective agonist of recombinant human mGlu2(Ki =149 nM)/mGlu3(Ki =92 nM).

More Information Supplier Page

LY404039 25 mg  | Purity Not Available

TargetMol

LY404039 is an effective agonist of recombinant human mGlu2(Ki =149 nM)/mGlu3(Ki =92 nM).

More Information Supplier Page

LY404039 50 mg  | Purity Not Available

TargetMol

LY404039 is an effective agonist of recombinant human mGlu2(Ki =149 nM)/mGlu3(Ki =92 nM).

More Information Supplier Page

Oprozomib 10 mg  | 99.05%

TargetMol

Oprozomib (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5（IC50=36 nM）/LMP7（IC50=82 nM）, is orally bioavailable. Oprozomib also has potential antineoplastic activity.

More Information Supplier Page

Oprozomib 25 mg  | 99.05%

TargetMol

Oprozomib (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5（IC50=36 nM）/LMP7（IC50=82 nM）, is orally bioavailable. Oprozomib also has potential antineoplastic activity.

More Information Supplier Page